Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 10/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6486937 | 1.00 | PTGES (0.58) | PTGESALOX5KMT2AMEN1ALDH1A1 | |
| SCHEMBL6475809 | 0.88 | KMT2A (0.53) | PTGESALOX5KMT2AMEN1ALDH1A1 | |
| SCHEMBL6483250 | 0.87 | PTGES (0.58) | PTGESALOX5ALDH1A1HPGDPTGS1 | |
| SCHEMBL6485138 | 0.87 | PTGES (0.58) | PTGESALOX5ALDH1A1HPGDPTGS1 | |
| SCHEMBL6476339 | 0.86 | PTGES (0.65) | PTGESALOX5ALDH1A1LMNAMAPT | |
| SCHEMBL6477030 | 0.85 | PTGS2 (0.49) | PTGESALOX5ALDH1A1LMNAMAPT | |
| SCHEMBL6475771 | 0.85 | PTGS2 (0.49) | PTGESALOX5ALDH1A1LMNAMAPT | |
| SCHEMBL6475565 | 0.84 | PTGES (0.57) | PTGESALOX5KMT2AMEN1ALDH1A1 | |
| SCHEMBL6993174 | 0.81 | PTGES (0.56) | PTGESALOX5KMT2AMEN1ALDH1A1 | |
| SCHEMBL7000442 | 0.81 | PTGES (0.56) | PTGESALOX5KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936632-B2 | Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof | MERCKLE GMBH (DE) | 2005-08-30 | — | — | US | disclosed |
| US-20040122002-A1 | Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof | MERCKLE GMBH (DE) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122002-A1 | Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof | PTGS1, PTGS2, PTGER1 | PTGES 6/4885ALOX5 62/4885KMT2A 3737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.